Pancreatic cancer remains one of the deadliest of the major cancers, with a five-year survival rate of only 13%. It’s a ...

Chronic pancreatitis is now recognized as a complex fibroinflammatory disorder involving genetic, environmental, and ...

Pancreatic cancer is known as one of the most dangerous cancers because it often develops quietly. Many people do not notice ...

A recent Nature article on novel GLP-1 therapies underscores a truth few key opinion leaders in medicine like to focus on: ...

The therapy shows efficacy in improving diarrhea, abdominal pain in GLP-1, GLP-1/GIP-treated patients with diabetes and/or ...

A second-grade teacher and grandmother experienced ambiguous symptoms like fatigue, back pain and weight loss. They were ...

THE WOODLANDS, TX, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted ...

The MarketWatch News Department was not involved in the creation of this content. Optune Pax concomitant with gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 ...

Through non-invasive, wearable arrays, Optune Lua uses TTFields to exert physical forces on the electrically charged components of the dividing cancer cells. [Image courtesy of Novocure] Novocure ...

Optune Pax concomitant with gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 years for locally advanced pancreatic cancer Phase 3 PANOVA-3 trial showed a ...

Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved Optune Pax ® for the treatment of adult patients with locally advanced pancreatic cancer concomitant ...

A plasterer who thought his back pain was from a pulled muscle or sleeping funny has been diagnosed with cancer - and told he has less than a year to live. Kris Cooke, 46, spent several months in ...